In this edition:
KEYNOTE-756: neoadjuvant pembrolizumab + chemotherapy + adjuvant pembrolizumab + endocrine therapy for early-stage, high-risk ER+/HER2– breast cancer
CheckMate 7FL: nivolumab + neoadjuvant chemotherapy for highrisk, ER+/HER2− breast cancer
KEYNOTE-522: 5-year EFS data
MonarchE: 5-year OS interim analysis
DESTINY-Breast: T-DXd for HER2+ metastatic breast cancer with brain metastases
BEGONIA: updated results of first-line Dato-DXd + durvalumab for unresectable, locally advanced/metastatic, triple-negative breast cancer
TROPION-Breast01: Dato-DXd in previously-treated, inoperable/ metastatic, HR+/HER2– breast cancer
RIGHT Choice: ribociclib + endocrine therapy in aggressive, HR+/HER2− advanced breast cancer – subgroup analysis
RIGHT Choice: QOL analysis
Please login below to download this issue (PDF)